Where is the live CopyMark page for USPTO serial 79246706?

The live record is at https://getcopymark.com/trademark/79246706. Use https://getcopymark.com/trademark/{serialNumber} for any 8-digit USPTO serial.

Who owns Serial No. 79246706?

According to the public USPTO record for serial number 79246706, the listed owner(s) include: Chengdu Kanghong Pharmaceuticals Group Co., Ltd., Chengdu Kanghong Pharmaceuticals Group Co., Ltd., Chengdu Kanghong Pharmaceuticals Group Co., Ltd..

What is USPTO serial number 79246706?

Serial number 79246706 is the USPTO application identifier for the mark Serial No. 79246706. It is used to track examination, publication, and registration of this trademark.

What is the current status of Serial No. 79246706?

Serial No. 79246706 (79246706) currently shows USPTO status code 709 on the public record. This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Which trademark classes cover Serial No. 79246706?

The public record lists International Classes: 005. Each class corresponds to categories of goods or services identified in the application or registration.

Trademark: Serial No. 79246706 Serial# 79246706 | status 709; last event C71T | Trademark Info & Attorney Guidance

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with Serial No. 79246706?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner

Monitor this mark, or talk with CopyMark about this registration.

Trademark Monitoring

(312) 319-4460

Not the owner?

File a new U.S. trademark application, or speak with our attorneys.

Start a new application

(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Alex Patel

Alex Patel Patel & Almeida, P.C.16830 Ventura Blvd., Suite 360Encino, CA 91436UNITED STATES

Goods and services

Class	Description	Status	First use
005	Royal jelly for pharmaceutical purposes; medicinal drinks; Radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; Chemico pharmaceutical preparations for the treatment of hepatitis, dizziness, cardiovascular diseases, cerebrovascular diseases, depression, schizophrenia, insomnia, Alzheimer's disease, cholecystitis, gallstones, stomach diseases, digestive diseases, restlessness, laryngitis, pharyngitis, tonsillitis, tracheitis, pneumonia, influenza, cough, diabetes, nephropathy, eye diseases, tumor, vision loss and blindness in the elderly; Depuratives for the body; Medicines for human purposes, namely, Hypoglycemic drugs, Organotherapeutic drugs, Antitumor drugs, Antiepileptic drugs, Anti-cancer drugs, Antiviral drugs for treating influenza, Cytostatic drugs for medical purposes, Antipyretic drugs with sedative effect, Cardiovascular drugs used in myocardial infarction, Cardiovascular drugs used in treating arrhythmias, Cardiovascular drugs used in angina pectoris, Cardiovascular drugs for use in treating hypertension, Medicines for treating intestinal disorders, Non-prescription medicines, namely, pills, tablets, capsules, caplets for the treatment of hepatitis, dizziness, cardiovascular diseases, cerebrovascular diseases, depression, schizophrenia, insomnia, cholecystitis, gallstones, stomach diseases, digestive diseases, restlessness, laryngitis, pharyngitis, tonsillitis, tracheitis, pneumonia, influenza, cough, diabetes, nephropathy, eye diseases, tumor, cancer, vision loss and blindness in the elderly, Medicines for the treatment of gastrointestinal diseases, Medicines for alleviating constipation;pesticides; Biomedicines for the treatment of hepatitis, dizziness, cardiovascular diseases, cerebrovascular diseases, depression, schizophrenia, insomnia, cholecystitis, gallstones, stomach diseases, digestive diseases, restlessness, laryngitis, pharyngitis, tonsillitis, tracheitis, pneumonia, influenza, cough, diabetes, nephropathy, eye diseases, tumor, cancer, vision loss and blindness in the elderly; Medicines for veterinary purposes, namely, Anti-infective products for veterinary use, Bacterial preparations for medical and veterinary use, Veterinary vaccines; Transdermal patches for use in the treatment of circulating the blood, relaxing the muscles and joints, reducing swelling and pain, treating bruises, eliminating fatigue before and after sports; Nutritive substances for microorganism for medical purposes; disinfectants; tissues impregnated with antibacterial preparations; dental lacquer; medicinal tea; Chemical preparations for pharmaceutical purposes for the treatment of hepatitis, dizziness, cardiovascular diseases, cerebrovascular diseases, depression, schizophrenia, insomnia, cholecystitis, gallstones, stomach diseases, digestive diseases, restlessness, laryngitis, pharyngitis, tonsillitis, tracheitis, pneumonia, influenza, cough, diabetes, nephropathy, eye diseases, vision loss and blindness in the elderly; Capsules for medicines, namely, Allergy capsules, Decongestant capsules, Herbal male enhancement capsules, Ginseng capsules for medical purposes; Pharmaceutical preparations for the treatment of central nervous system diseases, fundus diseases, vascular diseases, diabetes, schizophrenia, depression, anxiety disorders, insomnia, hypertension, hyperlipidemia, dyspepsia, gastritis, abdominal pain, gallbladder diseases, laryngitis, pharyngitis, gingivitis, constipation, respiratory diseases, influenza, cough, bronchitis, asthma, Alzheimer's disease, cancer, tumor; medicinal alcohol; gases for medical purposes; Dietetic substances in the nature of beverages adapted for medical use; bath preparations, medicated; diagnostic agents for medical purposes; Raw material medicine for the treatment of hepatitis, dizziness, cardiovascular disease, cerebrovascular disease, depression, schizophrenia, insomnia, cholecystitis, gallstones, stomach problems, digestive diseases, irritability, laryngitis, pharyngitis, tonsillitis, bronchitis, pneumonia, Influenza, cough, diabetes, nephropathy, eye disease, cancer, vision loss and blindness in the elderly; pearl powder for medical purposes; Prepared Chinese medicine for the treatment of dizziness, palpitation, insomnia, irritability, nausea, paralysis, back pain, shoulder pain, hypertension, hyperlipidemia, acute stroke, hemiplegia, cerebral infarction, stroke, Alzheimer's disease, heart disease, influenza, diabetes, depression, cancer, tumor, fundus diseases; Bag filled with Chinese medicine for the treatment of dizziness, palpitations, insomnia, irritability, nausea, paralysis, back pain, shoulder pain, hypertension, hyperlipidemia, acute stroke, hemiplegia, cerebral infarction, stroke, Alzheimer's disease, heart disease, influenza, diabetes, depression, cancer, tumor, fundus disease	SECTION 71 - CANCELLED	—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Date	Code	Event	What it means
Aug 28, 2026	C71T	CANCELLED SECTION 71	—
Feb 11, 2025	REM3	COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED	—
Jun 5, 2021	NREP	NEW REPRESENTATIVE AT IB RECEIVED	—
Aug 14, 2020	FINO	FINAL DECISION TRANSACTION PROCESSED BY IB	—
May 27, 2020	XXSS	GENERIC MADRID TRANSACTION SENT TO IB	—
May 27, 2020	XXCR	GENERIC MADRID TRANSACTION CREATED	—
May 11, 2020	FICR	FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB	—
Feb 11, 2020	R.PR	REGISTERED-PRINCIPAL REGISTER	Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 26, 2019	NPUB	OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED	—
Nov 26, 2019	PUBO	PUBLISHED FOR OPPOSITION	Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 6, 2019	NONP	NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED	—
Oct 21, 2019	ALIE	ASSIGNED TO LIE	—
Oct 16, 2019	CNSA	APPROVED FOR PUB - PRINCIPAL REGISTER	—
Oct 14, 2019	TEME	TEAS/EMAIL CORRESPONDENCE ENTERED	—
Oct 14, 2019	CRFA	CORRESPONDENCE RECEIVED IN LAW OFFICE	—
Oct 14, 2019	ERFR	TEAS REQUEST FOR RECONSIDERATION RECEIVED	—
May 20, 2019	GNFN	NOTIFICATION OF FINAL REFUSAL EMAILED	—
May 20, 2019	GNFR	FINAL REFUSAL E-MAILED	A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 20, 2019	CNFR	FINAL REFUSAL WRITTEN	A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 7, 2019	TEME	TEAS/EMAIL CORRESPONDENCE ENTERED	—
May 7, 2019	CRFA	CORRESPONDENCE RECEIVED IN LAW OFFICE	—
May 7, 2019	TROA	TEAS RESPONSE TO OFFICE ACTION RECEIVED	This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 5, 2019	RFNT	REFUSAL PROCESSED BY IB	—
Dec 16, 2018	RFCS	NON-FINAL ACTION MAILED - REFUSAL SENT TO IB	—
Dec 16, 2018	RFRR	REFUSAL PROCESSED BY MPU	—
Dec 7, 2018	MAFR	APPLICATION FILING RECEIPT MAILED	—
Dec 5, 2018	RFCR	NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW	—
Dec 4, 2018	CNRT	NON-FINAL ACTION WRITTEN	A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 3, 2018	DOCK	ASSIGNED TO EXAMINER	—
Dec 3, 2018	NWOS	NEW APPLICATION OFFICE SUPPLIED DATA ENTERED	—
Nov 29, 2018	REPR	SN ASSIGNED FOR SECT 66A APPL FROM IB	—

Serial No. 79246706